Siremadlin

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Siremadlin

CAS No. : 1448867-41-1

MCE 国际站：Siremadlin

产品活性：Siremadlin (NVP-HDM201) 是口服有效的选择性 p53-MDM2 抑制剂。

研究领域：Apoptosis  |  Metabolic Enzyme/Protease

作用靶点：MDM-2/p53  |  E1/E2/E3 Enzyme

In Vitro: Siremadlin (NVP-HDM201) disrupts both human and murine TP53- MDM2 interactions, with nanomolar cellular IC₅₀ values, blocking TP53 degradation.

In Vivo: Siremadlin (NVP-HDM201) is an imidazolopyrrolidinone analogue, showing a very advantageous in vivo profile. NVP-HDM201 has recently entered Phase 1 clinical trials in cancer patients. Constitutive PB mutagenesis in Arf^−/− mice provides a collection of spontaneous tumors with characterized insertional genetic landscapes. Tumors are allografted in large cohorts of mice to assess the pharmacologic effects of Siremadlin (NVP-HDM201). Sixteen out of 21 allograft models are sensitive to Siremadlin (NVP-HDM201) but ultimately relapse under treatment. A comparison of tumors with acquired resistance to Siremadlin (NVP-HDM201) and untreated tumors identified 87 genes that are differentially and significantly targeted by the PB transposon. Siremadlin (NVP-HDM201) administered either daily at a low dose or once at a high dose revealed a differentiated engagement of the p53 molecular response. In contrast to the daily low dose treatment regimen, the single high dose Siremadlin (NVP-HDM201) regimen results in a rapid and dramatic induction of p53-dependent PUMA expression and apoptosis. This is consistent with the finding that a single high dose Siremadlin (NVP-HDM201) treatment, administered orally or intravenously, results in a robust and sustained tumor regression. Overall, both daily and once every 3 weeks dosing regimen shows comparable long term efficacy in preclinical studies. The ongoing clinical trial is currently designed to compare both dosing regimens with regard to efficacy and tolerability.

相关产品：Drug Repurposing Compound Library Plus  |  Clinical Compound Library Plus  |  Bioactive Compound Library Plus  |  Apoptosis Compound Library  |  Metabolism/Protease Compound Library  |  Anti-Cancer Compound Library  |  Clinical Compound Library  |  Autophagy Compound Library  |  Anti-Aging Compound Library  |  Drug Repurposing Compound Library  |  Oxygen Sensing Compound Library  |  Ubiquitination Compound Library  |  Ferroptosis Compound Library  |  Pyroptosis Compound Library  |  Orally Active Compound Library  |  Glutamine Metabolism Compound Library  |  Anti-Pancreatic Cancer Compound Library  |  Anti-Blood Cancer Compound Library  |  Anti-Cancer Metabolism Compound Library  |  Transcription Factor-Targeted Library  |  Anti-Liver Cancer Compound Library   |  Anti-Colorectal Cancer Compound Library   |  Heterocyclic Compound Library  |  Highly Selective Inhibitors Library  |  TAK-243  |  Nutlin-3a  |  Minocycline hydrochloride  |  Pifithrin-α hydrobromide  |  Subasumstat  |  GSK3326595  |  Idasanutlin  |  Navtemadlin  |  Eprenetapopt  |  ML-792  |  CBL0137 hydrochloride  |  Mezigdomide  |  PYR-41  |  MD-224  |  Amifostine  |  UC2288  |  2-D08  |  Cbl-b-IN-1  |  Pifithrin-α, p-Nitro, Cyclic  |  RG7112  |  C25-140  |  Ginkgolic Acid  |  Milademetan  |  NSC319726  |  Indole-3-carbinol  |  HOIPIN-8  |  LS-102  |  PRT4165  |  RB-3

热门产品线：重组蛋白  |  化合物库  |  天然产物  |  荧光染料  |  PROTAC  |  同位素标记物

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Dye Reagents  |  PROTAC  |  Isotope-Labeled Compounds